Attovia
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1091 Industrial Rd Ste 310, San Carlos, ...Phone Number
(510) 399-5001Website
www.attovia.comRevenue
<$5 MillionStock Symbol
ATTOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
2
1
About Attovia
Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease. We leverage ATTOBODY, a novel biologics platform, to generate binders that offer an alternative to IgG-based medicines. ATTOBODIES are biparatopic biologics that utilize a proprietary spatial positioning technology. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, which drives strong potency in biologic activity, and functionalizes inactive epitopes. Attobodies are modular, nimble in multispecifics, and offer tunable half-life from hours to weeks with potential for quarterly dosing in patients. The high-throughput, evolution-based Attobody discovery platform significantly accelerates development and offers a high degree of diversity in lead candidates, expanding target biology coverage and derisking development.Explore more
Attovia Org Chart
Get the full picture
Sign in to uncover key details.
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Attovia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Attovia had a recent Job posting/layoffs
Product Launch: Get notified when Attovia launches new products
Check if Attovia has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Attovia, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Attovia recently announced quarterly report
Funding: Get notified immidiatlly once Attovia has new funding data
Check out if Attovia is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Attovia
Recommended Actions
Reach out to Masked Content who joined Attovia as Masked Content
Find more new buyers
Compare Similar Companies to Attovia
Compare insights from companies similar to Attovia, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$29.6M
51-200
Private
$277.8M
2020
Michael SecoraChief Financial Officer & Chief Corporate Development Officer
Company Profile Activity
Activity Insights
Attovia is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Attovia is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Attovia.
Attovia financials insights
Gather financial insights about Attovia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series B
$105M
2025
Series C
$90M
2026
IPO
$289M
Attovia Tech Stack
A closer look at the technologies used by Attovia
Most Recent Scoops
Open Position
Funding
Initial Public Offering (IPO)
IPO, Funding, Finance
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Attovia News & Media
Attovia Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences:Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026Goldman units trade Attovia Therapeutics (ATTO) shares, add swaps - Stock Titan
Filing shows 22.6M preferred shares converting at Attovia’s IPO plus 690,807 buys, 105,807 sells and long equity swaps by Goldman units.Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source
A newly public biotech is betting its entire future on a single antibody platform designed to silence the cytokine scientists call the itch cytokine, and its pipeline already stretches from skin disease into inflammatory bowel disease.
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Attovia
Sign Up For FreeTo access detailed company insights
Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease. We leverage ATTOBODY, a novel biologics platform, to generate binders that offer an alternative to IgG-based medicines. ATTOBODIES are biparatopic biologics that utilize a proprietary spatial positioning technology. The biparatopic binding mode of AT... Read More
